These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36439517)

  • 21. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report.
    Camus V; Etancelin P; Drieux F; Veresezan EL; Picquenot JM; Penther D; Viennot M; Ruminy P; Contentin N; Lemasle E; Leprêtre S; Dubois S; Penichoux J; Stamatoullas A; Zduniak A; Lanic H; Jardin F
    Clin Case Rep; 2023 Jun; 11(6):e7623. PubMed ID: 37361652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transplantation.
    Zain J
    Cancer Treat Res; 2019; 176():269-287. PubMed ID: 30596223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
    Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
    Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study.
    Bingjie W; Lihong W; Yongjin S; Huihui L; Jinping O; Xi'nan C
    Hematol Oncol; 2020 Aug; 38(3):272-276. PubMed ID: 32083758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.
    Mohammed Saleh MF; Kotb A; Abdallah GEM; Muhsen IN; El Fakih R; Aljurf M
    Curr Oncol; 2021 Dec; 28(6):5480-5498. PubMed ID: 34940095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study.
    Liu Y; Li P; Qian L
    Front Oncol; 2021; 11():758445. PubMed ID: 35047389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
    Ghione P; Faruque P; Mehta-Shah N; Seshan V; Ozkaya N; Bhaskar S; Yeung J; Spinner MA; Lunning M; Inghirami G; Moskowitz A; Galasso N; Ganesan N; van der Weyden C; Ruan J; Prince HM; Trotman J; Advani R; Dogan A; Horwitz S
    Blood Adv; 2020 Oct; 4(19):4640-4647. PubMed ID: 33002132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
    Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
    Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
    Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
    Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma].
    Xu T; Chen J; Jin ZM; Miao M; Fu CC; Qiu HY; Tang XW; Han Y; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):656-60. PubMed ID: 27587245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
    Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
    Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
    Foss F; Coiffier B; Horwitz S; Pro B; Prince HM; Sokol L; Greenwood M; Lerner A; Caballero D; Baran E; Kim E; Nichols J; Balser B; Wolfson J; Whittaker S
    Biomark Res; 2014; 2():16. PubMed ID: 25279222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma.
    Lee YP; Yoon SE; Cho J; Ko YH; Jo H; Kim SJ; Kim WS
    Ann Hematol; 2022 Jul; 101(7):1535-1543. PubMed ID: 35639152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.